(S) -Hydroxychloroquine

(S) -Hydroxychloroquine ((S) -HCQ) is the enantiomer of Hydroxychloroquine[1]. Hydroxychloroquine, a synthetic antimalarial agent, inhibits Toll-like receptor 7/9 (TLR7/9) signaling, and shows efficiently inhibits SARS-CoV-2 infection in vitro[2][3][4].

Product Specifications

CAS Number

[137433-24-0]

Product Name Alternative

(S) -HCQ

UNSPSC

12352005

Hazard Statement

H315-H319-H320

Target

Autophagy; Parasite; SARS-CoV; Toll-like Receptor (TLR)

Type

Reference compound

Related Pathways

Anti-infection; Autophagy; Immunology/Inflammation

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/s-hydroxychloroquine.html

Solubility

10 mM in DMSO

Smiles

CCN(CCO)CCC[C@@H](NC1=CC=NC2=CC(Cl)=CC=C12)C

Molecular Formula

C18H26ClN3O

Molecular Weight

335.87

Precautions

P264-P280-P302+P352-P305+P351+P338-P362

References & Citations

[1]Cardoso CD, et al. Enantioselective analysis of the metabolites of hydroxychloroquine and application to an in vitro metabolic study. J Pharm Biomed Anal. 2005 Apr 1;37 (4) :703-8.|[2]Manzo C, et al. Psychomotor Agitation Following Treatment with Hydroxychloroquine. Drug Saf Case Rep. 2017 Dec;4 (1) :6.|[3]Lamphier M, et al. Novel small molecule inhibitors of TLR7 and TLR9: mechanism of action and efficacy in vivo. Mol Pharmacol. 2014 Mar;85 (3) :429-40.|[4]Yao X, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) . Clin Infect Dis. 2020 Mar 9. pii: ciaa237.